India is poised for transformative changes as the government accelerates ease of doing business reforms, reshaping the corporate and regulatory landscape to integrate seamlessly into global supply chains and attract foreign direct investment (“FDI”). These efforts shine through strengthened ties with global powers, including the recent India-EU Free Trade Agreement negotiations, the India-US trade deal framework, and the amendments to Press Note 3 of 2020, which include calibrated relaxations on investments from land border sharing countries (LBS) by permitting certain categories of investments through the automatic route. Alongside these external-facing reforms aimed at facilitating foreign capital inflows, the domestic regulatory architecture supporting startups has also continued to evolve. In particular, the government has recently revised the Startup India recognition framework to bolster the Startup India Action Plan, placing greater emphasis on deep-tech ventures and broadening access to benefits for research and innovation-driven enterprises across a wider spectrum. These developments are complemented by the government’s continuing efforts to incentivise entrepreneurship through tax benefits and fiscal support measures aimed at driving growth.  

Buoyed by such momentum, investors can reasonably anticipate an uptick in capital, directly boosting funding opportunities for startups. In this evolving ecosystem, the Indian Simple Agreement for Future Equity (“iSAFE”), a battle-tested yet underappreciated early-stage financing medium, deserves renewed attention for its ability to achieve fastened transaction closing by delivering simple, valuation-free capital to early-stage ventures.

The iSAFE draws inspiration from the Y Combinator ‘SAFE’ model in the US but has been tailored for India’s regulatory environment, primarily structuring future equity in the form of quasi-equity instruments such as Compulsorily Convertible Preference Shares (“CCPS”) or Compulsorily Convertible Debentures (“CCD”) as opposed to pure play equity instruments under the SAFE model. This innovative early-stage financing medium allows startups to secure early-stage capital without immediate valuation or issuance of securities which issuance would take place upon the occurrence of defined trigger events, typically a priced financing round like Series A. Simply put, under iSAFE an investor provides capital to the company in exchange for a contractual right to be issued securities upon the occurrence of specified future events/ trigger events, as contractually agreed.

Key Distinction: Contract vs. Security

A common misconception positions iSAFE as a security itself, but it functions purely as a contractual right to future securities, operating one step prior to any issuance. At execution → the investor advances capital → no securities are issued immediately, and → the company commits to delivery on issuance of securities only on triggers like a subsequent funding round, dissolution, or liquidity event. 

Since no securities are issued at the time of execution of the iSAFE, the regulatory compliance requirements under the Companies Act, 2013 and rules framed thereunder (e.g., Sections 42, 55, 62 on private placements and rights issue) are not attracted immediately. This structure is aimed at minimizing upfront regulatory hurdles while ensuring eventual adherence at the time of issuance. 

The iSAFE structure defers compliance obligations rather than bypassing them for the straightforward reason that no securities are issued at the time of execution of the iSAFE.   Issuance itself stands postponed, contingent upon the trigger event’s occurrence. Consequent to such occurrence, the company’s obligation to issue the requisite securities crystallizes, thereby attracting the full panoply of regulatory and compliance obligations as may be applicable under law.  

For additional clarity, certain defining characteristics can be understood by elaborating the following distinctions: 

Aspect	iSAFE	CCPS/ CCDs (post trigger)
Nature	Contractual Entitlement	Actual security
Timing	Executed pre-issuance	Issued on the happening of the trigger event
Compliance	Deferred/ Contingent under the Indian Contract Act, 1872	Immediate under the Companies Act, 2013
Investor Right	Promise of Future Equity	Voting/ dividend preference, amongst others.

iSAFE: Legal Foundation as a Contingent Contract

Lacking specific statutory recognition and regulation, unlike debentures or shares, iSAFE fits squarely within general contract law, emerging as a contingent contract under Section 31 of the Indian Contract Act, 1872 (the “Contract Act”).

Section 31 of the Contract Act defines a contingent contract as:

A “contingent contract” is a contract to do or not to do something, if some event, collateral to such contract, does or does not happen.

A carefully drafted iSAFE mirrors this framework by tying the company’s obligation to issue securities to future trigger events, such as a priced funding round, thus crystallizing the contingent liability only upon their occurrence. 

Enforceability thus hinges on foundational principles enshrined under the Contract Act such as offer and acceptance, lawful consideration and object and the collateral nature of triggers to avert recharacterization as guaranteed debt.  Precise drafting is essential to avoid the frustration caused by ambiguous timelines, as the occurrence of non-collateral events could otherwise unravel the entire structure.

Should the contingency materialize yet the company fail to issue securities, investors retain recourse to specific performance under the Specific Relief Act, 1963, or damages for breach, thereby affirming iSAFE’s enforceability when meticulously structured and drafted. This underscores its purely contractual essence, distinct from the statutory rigors of securities issuance under the Companies Act, 2013 and rules framed thereunder since the obligation remains inchoate until the trigger activates, preserving operational flexibility by enabling immediate use of the funds invested, without regulatory circumvention.

Commercial Rationale and Incentive Alignment in iSAFE Structures

The validity and operational mechanics of an iSAFE reside firmly within the framework of the Contract Act where its enforceability turns on precise alignment with core principles thereunder. However, drafting an iSAFE demands surgical scrutiny, as this arrangement bridges cash-strapped early-stage startups with opportunistic risk-appetite investors, each harbouring distinct imperatives. For founders, iSAFE offers a lifeline, rapid seed capital sans the morass of immediate valuations or regulatory compliance.

For investors, wary of dilution risks, ironclad economic protections serve as the allure. The same is achieved by way of engrafting, inter alia, as contractually enforceable rights, valuation caps to cap effective pricing once triggered, conversion discounts rewarding early faith, or amplified liquidation preferences securing preferential payouts in exits. This alchemy of terms fuels the iSAFE’s allure and heavily hinges on artful negotiation and drafting.

The commercial rationale for both a company and an investor can thus be summarised below:

Company/ Promoters	Investors
Rapid Capital Infusion Seed-stage startups often require immediate capital. Negotiating valuation, structuring rights, and completing regulatory filings can delay funding.   iSAFE allows companies to raise capital quickly with minimal initial documentation.	Early Entry Investors can participate in early-stage funding, without the delays attributable to complex timelines, while simultaneously also safeguarding their interests for the future.
Deferral of Valuation Early-stage startups will not yet have sufficient financial metrics to justify a valuation.   The iSAFE structure allows valuation to be deferred to the next priced financing round, when a sounder and market-based valuation can be established.	Economic Upside iSAFE agreements typically include valuation caps or discounts, allowing early investors to convert their investment into equity at favourable terms.
Consolidated Compliance When the priced financing round occurs, the company will already be undertaking regulatory processes such as: issuing CCPS, passing board and shareholder resolutions, obtaining valuation reports, and making regulatory filings. Simultaneously with the above, the regulatory compliances required to issue securities pursuant to the iSAFE can also be consolidated.	Downside Protection Depending on the rights built into the iSAFE, the investors can benefit from liquidation preference rights, giving them priority over other stakeholders of the company in certain exit scenarios.

Conclusion

The iSAFE presents an alluring proposition for startups by facilitating unfettered access to seed capital, with regulatory compliance deftly deferred until a trigger event demands issuance. Yet, as with any contractual innovation, complexities lurk. Can this structure withstand scrutiny when foreign direct investments enter the fray, invoking FEMA regulations and the inexorable pricing guidelines? How might one deftly reconcile its validity against the peril of recharacterization as a disguised deposit, loan, or unregulated security?

These are intricacies that demand precise navigation. It remains undeniable that the iSAFE’s salvation lies in its meticulous alignment as a contingent contract under the Contract Act, painstakingly drafted for enforceability via specific performance, with due regard to the Specific Relief Act, 1963’s limits and exceptions on discretionary relief.

As India’s startup ecosystem surges forward, iSAFE stands poised for prominence. Yet, its true potency is unlocked by carving contractual certainty from regulatory ambiguity through bold, prescient drafting.